The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.


Ixazomib is an investigational, reversible 20S proteasome inhibitor. It is the first oral proteasome inhibitor under clinical investigation in multiple myeloma (MM). Under physiological conditions, the stable citrate ester drug substance, ixazomib citrate (MLN9708), rapidly hydrolyzes to the biologically active boronic acid, ixazomib (MLN2238). Preclinical studies have demonstrated antitumor activity in MM cell lines and xenograft models. In Phase I/II clinical studies ixazomib has had generally manageable toxicities, with limited peripheral neuropathy observed to date. Preliminary data from these studies indicate ixazomib is active as a single agent in relapsed/refractory MM and as part of combination regimens in newly diagnosed patients. Phase III studies in combination with lenalidomide-dexamethasone are ongoing.

DOI: 10.2217/fon.15.9
Citations per Year

280 Citations

Semantic Scholar estimates that this publication has 280 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Richardson2015TheIP, title={The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.}, author={Paul G Richardson and Philippe Moreau and Jacob P Laubach and Neeraj Gupta and Ai-Min Hui and Kenneth C. Anderson and Jes{\'u}s F San Miguel and Shaji K Kumar}, journal={Future oncology}, year={2015}, volume={11 8}, pages={1153-68} }